Indications
Ryeqo is indicated in adult women of reproductive age for: - treatment of moderate to severe symptoms of uterine fibroids, - symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Composition
- Active substance
- relugolix, norethisterone acetate, estradiol hemihydrate
- International name (INN)
- relugolix;estradiol;norethisterone acetate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ryeqo
- Active substance
- relugolix, norethisterone acetate, estradiol hemihydrate
- ATC code
- H01CC54
- Therapeutic area